Nexsen Limited (ASX:NXN) secures non-dilutive funding and research partnership through ARC-backed SAGE-Manufacturing program

Nexsen Limited has secured more than $1.5M in non-dilutive funding support through its admission as an industry partner to the ARC Industrial Transformation Training Centre for Sustainable and Green Economy Manufacturing (SAGE-Manufacturing), a 5-year national research centre led by Monash University in collaboration with RMIT University, the University of Melbourne, Deakin University and CSIRO.

The arrangement forms part of a structured research collaboration aimed at supporting Nexsen’s rapid diagnostics platform development and manufacturing scale-up, with the company contributing $35,000 in annual cash and $35,000 in in-kind support across the program period.

Highlights

• Admission as an industry partner to the ARC-funded SAGE-Manufacturing Centre
• More than $1.5M in non-dilutive funding support secured across the program
• 5-year research collaboration led by Monash University with RMIT, University of Melbourne, Deakin University and CSIRO
• Access to 2 full-time researchers embedded at Nexsen’s Australian R&D facility
• $35,000 annual cash contribution plus $35,000 in-kind contribution

Under the program, Nexsen will collaborate with SAGE-Manufacturing and RMIT University on research focused on applying catalysis science to its rapid diagnostics platform, including signal enhancement and manufacturing processes for diagnostic devices.

The company stated that the research will focus on detection sensitivity, reliability and performance consistency across its diagnostic pipeline.

Nexsen Executive Chairman Reece O’Connell said,

“Our mission at Nexsen is to become a global leader in rapid diagnostics. Closing the gaps that exist today where clinicians are forced to make critical decisions without the tools they need. Every improvement we make to our platform brings us closer to that goal, and SAGE-Manufacturing gives us access to world-class researchers and some of Australia’s leading scientific minds to keep pushing that standard further.”

Nexsen stated that its participation in the program supports its broader objective of developing scalable manufacturing capability to support future commercialisation of its diagnostic platform.

The company’s pipeline includes the GBS Rapid Sensor, a diagnostic for Group B Streptococcus detection, and diagnostic programs targeting acute kidney injury and chronic kidney disease.

Nexsen also noted ongoing development work across additional applications in human health, ag-tech and biosecurity, with catalysis science referenced in the announcement as a key discipline underpinning a large proportion of industrial chemical manufacturing processes.

—

Click here to view the latest ASX news.

Subscribe to The Day’s Play for daily ASX insights and capital markets updates.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.